D2560C00015 FluMist Annual Safety Study 2018

PHASE4CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

June 6, 2018

Primary Completion Date

December 27, 2018

Study Completion Date

December 27, 2018

Conditions
InfluenzaHealthy
Interventions
BIOLOGICAL

Bivalent influenza vaccine

A single dose of bivalent vaccine (10\^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered as intranasal spray on Day 1.

OTHER

Placebo

A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.

Trial Locations (2)

30281

Research Site, Stockbridge

97239

Research Site, Portland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT03564444 - D2560C00015 FluMist Annual Safety Study 2018 | Biotech Hunter | Biotech Hunter